APA

Platzbecker U., Wermke M., Radke J., Oelschlaegel U., Seltmann F., Kiani A., Klut I., Knoth H., Röllig C., Schetelig J., Mohr B., Graehlert X., Ehninger G., Bornhäuser M. & Thiede C. (20120508). Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. : Leukemia.

Chicago

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut I-M, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M and Thiede C. 20120508. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. : Leukemia.

Harvard

Platzbecker U., Wermke M., Radke J., Oelschlaegel U., Seltmann F., Kiani A., Klut I., Knoth H., Röllig C., Schetelig J., Mohr B., Graehlert X., Ehninger G., Bornhäuser M. and Thiede C. (20120508). Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. : Leukemia.

MLA

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut I-M, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M and Thiede C. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. : Leukemia. 20120508.